Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Triumeq

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

The companies will focus on advancing Kymera’s oral molecular glue degrader programme

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

Primary biliary cholangitis affects approximately 163,000 people in Europe

- PMLiVE

Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

The company gained access to the drug through its $4.3bn acquisition of CymaBay

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

Gilead appoints Dietmar Berger as chief medical officer

Berger most recently served as chief medical officer and global head of development at Sanofi

- PMLiVE

Cultivating Interest in Infectious Disease Education at ID Week 2024

IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

Medscape Education

- PMLiVE

Gilead and AI-focused Genesis partner to develop small molecule therapies

The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links